AnaptysBio
ANAB
116 hedge funds and large institutions have $441M invested in AnaptysBio in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 37 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
16% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 37
10.87% more ownership
Funds ownership: 104.23% → 115.1% (+11%)
4% less capital invested
Capital invested by funds: $460M → $441M (-$18.3M)
4% less funds holding
Funds holding: 121 → 116 (-5)
14% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 22
31% less call options, than puts
Call options by funds: $2.44M | Put options by funds: $3.52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$21.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$16.2M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$11.4M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11.3M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$16.8M |
| 2 |
Morgan Stanley
New York
|
-$8.25M |
| 3 |
PA
Perceptive Advisors
New York
|
-$7.58M |
| 4 |
Millennium Management
New York
|
-$6.11M |
| 5 |
Goldman Sachs
New York
|
-$2.95M |
ANAB Hedge Fund Activity: Q1 2020 in Review
116 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2020, worth a combined $441M — down 4% from $460M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ANAB and 19 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 43 added.
The largest buyer was Aquilo Capital Management, opening a new position worth an estimated $21.8M. The largest seller was Federated Hermes, cutting an estimated $16.8M.
- 116 institutional investors held AnaptysBio (ANAB) as of Q1 2020, down from 121 in Q4 2019.
- Funds reported $441M of AnaptysBio stock for Q1 2020, down 4% quarter-over-quarter.
- 19 funds opened new AnaptysBio positions in Q1 2020 and 22 closed out, a net change of -3 holders.
- The largest AnaptysBio buyer in Q1 2020 was Aquilo Capital Management, an estimated $21.8M added.
- The largest AnaptysBio seller in Q1 2020 was Federated Hermes, an estimated $16.8M sold.
Based on aggregated 13F filings for Q1 2020.